102.30
0.05 (0.05%)
| Previous Close | 102.25 |
| Open | 102.25 |
| Volume | 1,794,994 |
| Avg. Volume (3M) | 5,501,872 |
| Market Cap | 19,428,497,408 |
| Price / Earnings (Forward) | 188.68 |
| Price / Sales | 6.01 |
| Price / Book | 8.22 |
| 52 Weeks Range |
| Profit Margin | -36.06% |
| Operating Margin (TTM) | -11.53% |
| Diluted EPS (TTM) | -5.53 |
| Quarterly Revenue Growth (YOY) | 10.90% |
| Total Debt/Equity (MRQ) | 105.93% |
| Current Ratio (MRQ) | 2.73 |
| Operating Cash Flow (TTM) | 323.66 M |
| Levered Free Cash Flow (TTM) | 163.08 M |
| Return on Assets (TTM) | -1.83% |
| Return on Equity (TTM) | -36.89% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Exact Sciences Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | 3.0 |
| Price Volatility | -3.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.10 |
|
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 0.92% |
| % Held by Institutions | 98.89% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 105.00 (Mizuho, 2.64%) | Hold |
| 105.00 (Evercore ISI Group, 2.64%) | Hold | |
| Median | 105.00 (2.64%) | |
| Average | 105.00 (2.64%) | |
| Total | 2 Hold | |
| Avg. Price @ Call | 101.98 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Mizuho | 20 Jan 2026 | 105.00 (2.64%) | Hold | 102.35 |
| Evercore ISI Group | 05 Jan 2026 | 105.00 (2.64%) | Hold | 101.61 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CONROY KEVIN T | 103.27 | 103.27 | 6,985 | 721,341 |
| Aggregate Net Quantity | 6,985 | |||
| Aggregate Net Value ($) | 721,341 | |||
| Aggregate Avg. Buy ($) | 103.27 | |||
| Aggregate Avg. Sell ($) | 103.27 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| CONROY KEVIN T | Officer | 25 Feb 2026 | Acquired (+) | 13,181 | 103.27 | 1,361,202 |
| CONROY KEVIN T | Officer | 25 Feb 2026 | Disposed (-) | 6,196 | 103.27 | 639,861 |
| Date | Type | Details |
|---|---|---|
| 03 Feb 2026 | Announcement | Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests |
| 03 Feb 2026 | Announcement | Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide |
| 11 Dec 2025 | Announcement | Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |